Cold aid nothing to sneeze at |

Cold aid nothing to sneeze at

Easy to catch. Hard to get rid of.

It’s that time of year again when the common cold invades, spreading germs, discomfort and crankiness, while somehow evading a cure or an effective treatment.

Allegheny General Hospital allergy researchers say they may have found the answer under their noses — a common allergy medicine they expect will drastically reduce the severity of cold symptoms.

The researchers found cold sufferers have elevated levels of leukotriene, a chemical successfully combated by montelukast, which is sold under the name Singulair.

Leukotriene levels are highest when symptoms are the worst, said Dr. Deborah Gentile, one of the researchers, who reported their findings in the current issue of the Annals of Allergy, Asthma and Immunology.

Each year, Americans suffer about one billion colds that various studies have translated to 45 million days of restricted activity and 22 million days out of school, according to Allegheny General.

Adults average two to four colds each year, while children get hit six to 10 times, according to the hospital. Colds often progress to sinus and middle-ear infections and worsen asthma. Cold season typically is from mid-September through November, Gentile said.

In the AGH study, funded by the National Institutes of Health, 66 previously healthy adults were given one of three viruses so leukotriene levels could be measured as symptoms progressed.

Gentile and her fellow researchers now are seeking 80 stuffed-up adults in the early stages of a cold to determine whether the drug will reduce symptoms.

Again, they only had to look under their own noses. The first volunteer was one of their research associates, Asha Patel, who coincidentally caught a cold as the study kicked off.

“We just opened the study yesterday and she came in to work today with a cold, so she got to be in it,” Gentile said.

Study volunteers get paid for time, travel and parking expenses, but the hospital does not release the amount. Neither doctors nor study participants know who gets the medication and who gets placebos until the study has been completed. The study is being funded by Merck & Co., the manufacturer of Singulair.

Potential volunteers should call (412) 359-6642 for more information.

Allegheny General also is participating in a worldwide study of the drug’s effects on infants hospitalized with respiratory syncytial virus, or RSV.

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.